Vernon Hunter, MD
Cardiovascular Disease · Huntsville, ALNPI 1740251966
Payments from drug & device makers
Across 497 payments — averaging $1564.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$401K
- Novartis$188K
- Amgen$184K
- Johnson & Johnson$929
- Pfizer$647
- Regeneron Healthcare Solutions, Inc.$455
- plus $3K from 20 others
What the payments were for
- Travel & lodging$1952%
- Food & beverage$8,00398%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 47 | $400,806 |
| Novartis | 125 | $188,079 |
| Amgen | 56 | $183,789 |
| Johnson & Johnson | 60 | $929 |
| Pfizer | 41 | $647 |
| Regeneron Healthcare Solutions, Inc. | 19 | $455 |
| Boehringer Ingelheim | 23 | $449 |
| AstraZeneca | 23 | $361 |
| E.r. Squibb & Sons, L.L.C. | 17 | $274 |
| Sanofi-aventis U.S. LLC | 13 | $239 |
| Novo Nordisk | 12 | $229 |
| Bayer | 10 | $198 |
| Esperion Therapeutics, Inc. | 8 | $154 |
| Merck | 7 | $149 |
| Abbott | 2 | $145 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $139 |
| Boston Scientific | 3 | $137 |
| United Therapeutics Corporation | 4 | $122 |
| Otsuka America Pharmaceutical, Inc. | 5 | $108 |
| Heartflow, Inc. | 2 | $74 |
| Scpharmaceuticals Inc. | 3 | $50 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Gilead | 3 | $39 |
| Chiesi USA, Inc. | 3 | $38 |
| Recor Medical Inc | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$777,686 in reported general payments places this provider in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 718 | $697,563 |
| EntrestoSacubitril/Valsartan | 305 | $369,563 |
| FarxigaDapagliflozin Propanediol | 207 | $201,162 |
| XareltoRivaroxaban | 178 | $179,238 |
| JardianceEmpagliflozin | 143 | $149,409 |
| Repatha SureclickEvolocumab | 150 | $108,493 |
| MounjaroTirzepatide | 16 | $20,427 |
| Metoprolol Succinate | 782 | $14,835 |
| Valsartan | 395 | $13,957 |
| Candesartan Cilexetil | 109 | $11,227 |
| Repatha SyringeEvolocumab | 12 | $11,120 |
| Ranolazine ErRanolazine | 64 | $10,312 |
| MultaqDronedarone Hcl | 11 | $9,576 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $8,823 |
| Rosuvastatin Calcium | 452 | $8,815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $647 | $697,563718 claims |
| NovartisEntresto | $188,079 | $369,563305 claims |
| AstraZenecaFarxiga | $361 | $201,162207 claims |
| Johnson & JohnsonXarelto | $929 | $179,238178 claims |
| Boehringer IngelheimJardiance | $449 | $149,409143 claims |
| Sanofi-aventis U.S. LLCMultaq | $239 | $9,57611 claims |
| Esperion Therapeutics, Inc.Nexlizet | $154 | $8,82312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Huntsville
- Walter HaughtHuntsville$1.6M
- Shi-Chi ChengHuntsville$1.2M
- Phillip LaneyHuntsville$283K
- Michael RidnerHuntsville$216K
- Enrique VelasquezHuntsville$124K
- James MurphyHuntsville$115K
- Rashida AbbasHuntsville$45K
- Warren StricklandHuntsville$14K
- Mustafa AhmedBirmingham$2.5M
- Brian FoleyAlexander City$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.